Company intelligence / Profile preview
Eldec Pharmaceuticals
Chapel Hill, North Carolina, United Stateseldecpharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Eldec’s lead candidate ELD607 is a first-in-class peptidomimetic modulator of Orai1. In preclinical animal models of chronic lung disease and sepsis, ELD607 has shown the ability to reduce inflammation, improve survival in bacterial pneumonia and sepsis models, and reverse existing lung damage without causing immunosuppression. The compound has also demonstrated anti-bacterial and anti-inflammatory effects in multiple animal studies but has not yet entered clinical trials.[3][8]
- Therapeutic areas
- OtherPulmonologyInfectious Diseases
- Modalities
- Peptidomimetics (peptide-based drugs)Small molecules[2][3][10]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Eldec Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eldec Pharmaceuticals.